Natera Q1 Net Loss Narrows, Revenue Rises; Increases Full Year Revenue Outlook

Published on 09/05/2025 at 06:56

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Natera, Inc.

Natera Presents Data At ESMO GI on its Tissue-Free Latitude? MRD	07/07	CI
Natera to Present Clinical and Economic Utility of Signatera At Esmo Gi, Highlights Innovations in Mrd	02/07	CI
Natera, Inc.(NasdaqGS:NTRA) dropped from Russell 2500 Growth Index	30/06	CI
Natera, Inc.(NasdaqGS:NTRA) dropped from Russell 2500 Index	30/06	CI
Natera, Inc.(NasdaqGS:NTRA) dropped from Russell 2500 Growth Benchmark	30/06	CI
Natera, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 02:00 PM	10/06
Sector Update: Health Care Stocks Advance Late Afternoon	05/06	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	05/06	MT
Sector Update: Health Care	05/06	MT
Natera, Inc. Announces Medicare Coverage for Signatera Genome	04/06	CI
Natera Says Signatera Cancer Test Approved for Medicare Coverage	04/06	MT
Natera Inc - Signatera Assay Now Covered By Medicare	04/06	RE
Natera, Inc. Announces Results from A Large-Scale Pan-Cancer Study of Its Signatera Genome Assay	03/06	CI
Natera, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 10:30 AM	23/05
Natera Q1 Net Loss Narrows, Revenue Rises; Increases Full Year Revenue Outlook	09/05	MT
Natera, Inc., Q1 2025 Earnings Call, May 08, 2025	09/05
Earnings Flash (NTRA) NATERA INC. Reports Q1 Revenue $501.8M, vs. FactSet Est of $446.2M	09/05	MT
Natera, Inc. Provides Earnings Guidance for the Year 2025	09/05	CI
Natera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	09/05	CI
Natera, Inc. Announces to Present Multiple Datasets in Breast Cancer Together with its Collaborators at 2025 ESMO Breast Cancer Annual Congress in Munich, Germany	09/05	CI
Natera, Inc. Announces the American Journal of Transplantation Publishes New Study Evaluating the Performance of Prospera Heart with Dqs to Detect Allograft Rejection	07/05	CI
Natera, Inc. Announces Results of Study Led by Stanford University School of Medicine for the Evaluation of Signatera	05/05	CI
Natera, Inc. Announces the Results of Its Define-HT Clinical Trial in Heart Transplantation	30/04	CI
Natera Announces Broad Clinical Launch of Ultra-S sensitive Signatera Genome MRD Test	24/04	CI
Natera, Inc. to Present Data from 8 Studies at 2025 AACR Annual Meeting	23/04	CI